Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients
| Autor: | Barbara Del Pin, Federico Pea, Eleonora Zamparini, Pierluigi Viale, Piergiorgio Cojutti, Mario Furlanut |
|---|---|
| Přispěvatelé: | Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M |
| Rok vydání: | 2012 |
| Předmět: |
Microbiology (medical)
Drug Adult Male medicine.medical_specialty Drug-Related Side Effects and Adverse Reactions media_common.quotation_subject Cmax THERAPEUTIC DRUG MONITORING Gastroenterology TDM chemistry.chemical_compound Cmin Plasma Internal medicine Acetamides polycyclic compounds medicine Humans Pharmacology (medical) Oxazolidinones media_common Retrospective Studies Pharmacology medicine.diagnostic_test business.industry Linezolid Retrospective cohort study Bacterial Infections Middle Aged bacterial infections and mycoses Thrombocytopenia Surgery Anti-Bacterial Agents Infectious Diseases Treatment Outcome chemistry Therapeutic drug monitoring Therapy Toxicity Female Drug Monitoring Rifampin business Rifampicin medicine.drug |
| Zdroj: | The Journal of antimicrobial chemotherapy. 67(8) |
| ISSN: | 1460-2091 |
| Popis: | BJECTIVES: Prolonged treatment with linezolid may cause toxicity. The purpose of this study was to define pharmacodynamic thresholds for improving safety outcomes of linezolid. METHODS: We performed a retrospective study of patients who had trough (C(min)) and peak (C(max)) plasma levels measured during prolonged linezolid treatment. Dosage adjustments were performed when C(min) ≥10 mg/L and/or AUC₂₄ ≥400 mg/L · h. Patients were divided into two subgroups according to the absence or presence of co-treatment with rifampicin (the linezolid group and the linezolid + rifampicin group, respectively). Data on demographic characteristics, disease, microbiology and haematochemical parameters were collected and outcomes in relation to drug exposure were compared between groups. RESULTS: A total of 45 patients were included. Dosage adjustments were needed in 40% versus 0% of patients in the linezolid group (n = 35) versus the linezolid + rifampicin group (n = 10), respectively. Patients in the linezolid group had either significantly higher C(min) [3.71 mg/L (1.43-6.38) versus 1.37 mg/L (0.67-2.55), P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|